Screening for other cancer sites
The Mass Screening Registry also monitors scientific evidence obtained about the screening methods and results of other cancer sites. The most scientific evidence has so far accumulated concerning screenings for the prostate, lung, stomach, and ovarian cancers.
The Mass Screening Registry has participated in an international prostate cancer screening study. Men aged 55-67 years were invited to screening over the 1996-2007 period. The study investigated the suitability of the PSA test for prostate cancer screening. For more information on the study: European Randomized Study of Screening for Prostate Cancer (ERSPC).
Other scientific evidence on benefits and harms of cancer screening has been compiled in the publication Cancer in Finland 2016.